Welcome to our dedicated page for BOSTON SCIENTIFIC SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BOSTON SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BOSTON SCIENTIFIC's regulatory disclosures and financial reporting.
Butcher Arthur C reported multiple insider transaction types in a Form 4 filing for BSX. The filing lists transactions totaling 57,681 shares at a weighted average price of $74.12 per share. Following the reported transactions, holdings were 5,386 shares.
Boston Scientific executive Vance R. Brown, EVP, GC and Corporate Secretary, reported equity compensation changes tied to restricted stock units and options. On February 12, 2026, 1,442 restricted stock units were exercised into 1,442 shares of common stock, and 488 shares were disposed of to cover tax withholding at $74.12 per share.
Following these transactions, Brown directly held 34,405 shares of common stock. He also received new grants of 7,420 restricted stock units and 17,510 stock options with a $74.12 exercise price, each vesting in four equal annual installments beginning February 12, 2027.
Boston Scientific Corporation provides an overview of its global medical device business, strategy and key transactions in its annual report for the year ended December 31, 2025. The company highlights a definitive agreement to acquire Penumbra for $14.500 billion, funded with approximately $11.000 billion of cash and new debt and the balance in stock.
Boston Scientific reports an aggregate market value of common stock held by non‑affiliates of about $158.7 billion based on a $107.41 share price on June 30, 2025, and 1,483,885,456 shares outstanding as of January 30, 2026. Total debt was $11.436 billion as of December 31, 2025. The company employed roughly 59,000 people worldwide at year‑end 2025, with 36 percent of net sales generated outside the U.S.
The report details two completed 2025 acquisitions—Bolt Medical and SoniVie—to expand intravascular and hypertension technologies, and explains a 2023 restructuring program expected to generate annual pre‑tax savings of $350 million to $400 million from total charges of $700 million to $800 million. Extensive risk disclosures cover competition, pricing pressure, regulation, cybersecurity, supply chain, climate and human‑capital challenges.
Boston Scientific Corporation disclosed that director Yoshiaki Fujimori has informed the company he will not stand for re-election at the 2026 Annual Meeting of Stockholders. He has served on the Board since July 2016 and currently chairs the Risk, Science and Technology Committee.
Mr. Fujimori will continue as a director and in his committee roles until the 2026 Annual Meeting. The company states that his decision is not due to any disagreement with the company. The Board and its Nominating and Governance Committee will continue reviewing Board size and composition and may consider adding directors after his departure.
Boston Scientific Corporation furnished a Form 8-K to announce it issued a press release with financial results for the fourth quarter and full year ended December 31, 2025. The press release, dated February 4, 2026, is attached as Exhibit 99.1 and is furnished rather than filed for liability purposes.
Boston Scientific’s Chairman, President & CEO Michael F. Mahoney reported routine equity transactions in company stock. On February 2, 2026, he exercised stock options for 49,407 shares at $24.55 and 46,347 shares at $27.09, converting them into common stock.
That same day, he sold 1,200 shares at a weighted average price of $94.0567 and 159,701 shares at a weighted average price of $93.4905. The filing states these trades were made under a pre-established Rule 10b5‑1 trading plan adopted on August 29, 2025.
After these transactions, Mahoney directly owned 1,411,735 Boston Scientific common shares and had stock options for 231,739 and 98,814 shares from prior grants. He also indirectly held 213,679 shares through a trust.
A shareholder of BSX filed a notice of proposed sale of 160,901 shares of common stock, with an aggregate market value of $15,043,390.17. The planned sales are to be executed through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 02/02/2026.
The shares to be sold were acquired through a mix of performance shares, restricted stock, and a stock option exercise, all obtained directly from the issuer between 2018 and 2026, with the stock option portion paid in cash.
Boston Scientific Corporation has entered into a definitive agreement to acquire Penumbra, Inc. in a cash-and-stock deal valued at $14.5 billion. The company plans to fund about 73% of the price in cash and 27% in stock, and expects the transaction to close sometime this year, subject to conditions such as regulatory approvals.
The acquisition is intended to rebuild Boston Scientific’s neurovascular portfolio, adding devices that treat stroke-causing blood clots in the brain and pulmonary embolism clots in the lungs, and to complement its existing cardiovascular and brain-related businesses. Penumbra expects roughly $1.4 billion in 2025 revenue, growing more than 17% compared with 2024. Boston Scientific anticipates the deal will slightly dilute earnings in the first full year after closing, become neutral to slightly beneficial in the second year, and more beneficial thereafter, while potentially supporting its long-range goal of sustaining organic sales growth of 10% and higher.
Boston Scientific Corporation entered into a definitive Agreement and Plan of Merger to acquire Penumbra, Inc., which will become a wholly owned subsidiary. At closing, each Penumbra share can receive either $374.00 in cash or 3.8721 Boston Scientific shares, with a proration so that about 73.26% of shares receive cash consideration and 26.74% receive stock.
Completion of the merger depends on Penumbra stockholder approval, required antitrust and other regulatory clearances, effectiveness of a Form S-4 registration statement, NYSE listing of new Boston Scientific shares and other customary conditions, including no material adverse effects. The agreement includes reciprocal termination fees: Penumbra may owe $525,000,000 in certain superior-offer scenarios, while Boston Scientific may owe $900,000,000 if specified regulatory-related conditions prevent closing after Penumbra approval and other conditions are met.
Boston Scientific Corporation reported that it has signed a definitive agreement to acquire Penumbra, Inc. through a merger of a wholly owned Boston Scientific subsidiary with Penumbra. The transaction was announced in a joint press release and detailed in an investor presentation made available on the company’s website.
The acquisition is subject to closing conditions, including required regulatory approvals and clearances and other conditions outlined in the definitive agreement. Boston Scientific plans to file a Form S-4 registration statement containing a proxy statement/prospectus for Penumbra stockholders, who will receive detailed information before voting on the proposed transaction.
The filing emphasizes that statements about the expected financial and business impact and anticipated benefits of the transaction are forward-looking and subject to numerous risks, including regulatory outcomes, integration of Penumbra’s operations, and potential business disruptions following the announcement and closing.